

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/240356 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 9/00 (2006.01)
A61P 1/04 (2006.01) A61P 11/00 (2006.01)
A61P 3/10 (2006.01) A61P 13/12 (2006.01)
A61P 5/14 (2006.01) A61K 31/5377 (2006.01)
A61P 7/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/IB2021/054516

(22) International Filing Date:

25 May 2021 (25.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(30) Priority Data:

62/704,796 28 May 2020 (28.05.2020) US
63/037,366 10 June 2020 (10.06.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **DOWTY, Martin Eugene**; c/o Pfizer Inc., 610
Main Street, Cambridge, Massachusetts 02139 (US). **MAL-
HOTRA, Bimal Kumar**; c/o Pfizer Inc., 235 East 42nd
Street, New York, New York 10017 (US). **SAMARDJIEV,
Ivan Jordan**; c/o Pfizer Inc., 445 Eastern Point Road,
Building 98, Groton, Connecticut 06340 (US). **SAMAS,
Brian Matthew**; c/o Pfizer Inc., 445 Eastern Point Road,
Building 98, Groton, Connecticut 06340 (US). **STRO-
HBACH, Joseph Walter**; c/o Pfizer Inc., 610 Main Street,
Cambridge, Massachusetts 02139 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES

(57) Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceu-
tical compositions containing them.

WO 2021/240356 A1